IRIS
GIACOMELLI, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.044
AS - Asia 9.945
EU - Europa 9.509
SA - Sud America 1.098
AF - Africa 128
Continente sconosciuto - Info sul continente non disponibili 39
OC - Oceania 30
Totale 37.793
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.875
SG - Singapore 4.171
IE - Irlanda 2.532
CN - Cina 2.468
TR - Turchia 1.516
SE - Svezia 1.148
RU - Federazione Russa 1.146
HK - Hong Kong 1.052
IT - Italia 1.052
DE - Germania 1.012
BR - Brasile 972
UA - Ucraina 830
GB - Regno Unito 713
FI - Finlandia 383
FR - Francia 318
VN - Vietnam 205
IN - India 196
CA - Canada 101
BE - Belgio 63
JP - Giappone 60
NL - Olanda 53
BD - Bangladesh 52
AR - Argentina 48
ZA - Sudafrica 45
ES - Italia 43
MX - Messico 42
PL - Polonia 36
EU - Europa 34
IQ - Iraq 28
RO - Romania 26
CZ - Repubblica Ceca 23
AU - Australia 21
ID - Indonesia 20
LT - Lituania 20
PK - Pakistan 19
GR - Grecia 18
EC - Ecuador 17
VE - Venezuela 17
KR - Corea 16
AT - Austria 15
MA - Marocco 15
CH - Svizzera 14
CO - Colombia 13
EG - Egitto 13
MY - Malesia 13
UZ - Uzbekistan 13
NP - Nepal 12
PT - Portogallo 12
BG - Bulgaria 11
DZ - Algeria 11
JO - Giordania 11
AE - Emirati Arabi Uniti 10
IL - Israele 9
LB - Libano 9
NZ - Nuova Zelanda 9
SA - Arabia Saudita 9
AL - Albania 8
KE - Kenya 8
PE - Perù 8
QA - Qatar 8
TN - Tunisia 8
BO - Bolivia 7
ET - Etiopia 7
JM - Giamaica 7
PY - Paraguay 7
DK - Danimarca 6
AZ - Azerbaigian 5
HR - Croazia 5
IR - Iran 5
KW - Kuwait 5
PH - Filippine 5
SN - Senegal 5
UY - Uruguay 5
CI - Costa d'Avorio 4
CL - Cile 4
GE - Georgia 4
HU - Ungheria 4
MK - Macedonia 4
OM - Oman 4
A2 - ???statistics.table.value.countryCode.A2??? 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
HN - Honduras 3
KZ - Kazakistan 3
LU - Lussemburgo 3
NG - Nigeria 3
PS - Palestinian Territory 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
CG - Congo 2
EE - Estonia 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
NI - Nicaragua 2
RS - Serbia 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AG - Antigua e Barbuda 1
Totale 37.772
Salva come PNG Salva come JPEG
Città #
Jacksonville 3.347
Chandler 2.675
Dublin 2.525
Singapore 2.144
Dallas 1.366
Hong Kong 1.047
Boardman 993
Santa Clara 982
Izmir 830
Ashburn 565
Nanjing 554
San Mateo 512
Wilmington 495
Lawrence 444
Princeton 444
New York 387
Beijing 353
Ann Arbor 291
Moscow 276
Nanchang 221
The Dalles 172
Los Angeles 167
Milan 165
L'aquila 164
L’Aquila 162
Dearborn 142
Woodbridge 135
Seattle 130
Hefei 121
Verona 120
Shenyang 119
Des Moines 110
Hebei 103
Kunming 90
Tianjin 90
São Paulo 86
Jiaxing 84
Munich 78
Shanghai 73
Council Bluffs 72
Mountain View 65
Helsinki 61
Changsha 60
Dong Ket 60
Tokyo 59
Columbus 58
Brussels 57
Jinan 57
Zhengzhou 56
Norwalk 55
Ho Chi Minh City 52
Rome 44
Hangzhou 43
Frankfurt am Main 42
Phoenix 38
Pune 37
Ningbo 34
Rio de Janeiro 34
Philadelphia 33
Hanoi 32
Montreal 32
Chicago 31
Guangzhou 31
Houston 31
Warsaw 31
Johannesburg 29
Brooklyn 28
London 28
San Francisco 28
Stockholm 25
Belo Horizonte 24
Atlanta 21
Kitzingen 21
Lanzhou 21
Toronto 21
Chennai 20
Denver 20
Amsterdam 19
Brno 19
Mumbai 19
Orem 19
San Jose 18
Bremen 17
Manchester 17
Pescara 17
Taizhou 17
Ankara 16
Boston 16
Mexico City 16
Redwood City 16
Bucharest 15
Falkenstein 15
Brasília 14
Changchun 14
Washington 14
Fremont 13
Fuzhou 13
Guarulhos 13
New Delhi 13
Tashkent 13
Totale 24.616
Salva come PNG Salva come JPEG
Nome #
------- 335
EULAR Textbook on Rheumatic Diseases – Third Edition (2018) 269
Studio dell’espressione della chemochina SDF-1 e del suo recettore CXCR4 nella cute e nelle cellule endoteliali microvascolari di pazienti affetti da sclerosi sistemica (SSc). 172
Aumento dei linfociti circolanti gamma-delta Vdelta1+ in corso di malattie infiammatorie intestinali 157
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 148
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 145
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 139
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 139
Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis 137
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 136
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 132
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 131
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 131
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 130
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 128
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 128
Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis. 126
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 125
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 123
Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: Results of a large multicentre study 121
Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? 121
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 119
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 119
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis 116
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 114
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 114
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis 114
Cardiovascular disease in primary sjögren’s syndrome 113
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 112
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 112
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 111
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 110
Cytokine production in patients with monoclonal gammapathies. 110
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 109
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 109
Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. 109
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 109
Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis 109
Stem cell therapies for systemic sclerosis 108
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 108
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort 107
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. 107
Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case–control study 107
Linfociti T Gamma-Delta (G/D) in pazienti con malattie infiammatorie intestinali (IBD) 106
GM-CSF and pregnancy: evidence of significantly reduced blood concentrations in unexplained recurrent abortion efficiently reverted by intravenous immunoglobulin treatment. 106
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 106
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences 106
Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: a case-control study 105
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 105
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 105
Comment on 'Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?' 104
Malattie dell'apparato cardiovascolare 104
Inosine pranobex in the combination therapy of HIV infection. 104
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. 104
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 103
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 102
Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis 102
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 102
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 102
Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization 101
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells 101
GAMMA/DELTA T CELL APOPTOSIS IN SYSTEMIC SCLEROSIS PATIENTS 101
A comprehensive review on adult onset Still's disease 101
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 101
Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms 100
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 100
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 100
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 100
Biotech on the Rise: The Treatment of Psoriasis with Biological Drugs 99
Diagnostic and interventional radiology fundamentals of synovial pathology 99
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 99
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 98
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis 98
Vitamin D and systemic lupus erythematosus - The hype and the hope 98
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 98
Dissecting the clinical heterogeneity of adult-onset Still's disease, results from a multi-dimensional characterisation and stratification 98
CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. 97
Combined approach to the initial stage raynaud’s phenomenon diagnosis by means of dynamic digital telehermograpy, capillaroscopy and pletismography. Preliminary findings. 97
Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients 97
Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. 97
The role of cytokines in the patogenesis of monoclonal gammapathies. 97
ALTERAZIONI DELLE SOTTOPOLAZIONI LINFOCITARIE IN CORSO DI SCLERODERMIA 97
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 97
Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander? 97
NK activity and antibody-dependent cellular citotoxicity (ADCC) in inflammatory bowel disease(IBD) 96
Neoplasie e sistema immune 96
EFFICACY AND SAFETY OF RITUXIMAB TREATMENT IN EARLY PRIMARY SJOGREN'S SYNDROME: A CLINICAL, HISTOLOGICAL AND MOLECULAR STUDY 96
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. 96
The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis 96
Cyclosporin (CyA) and H2 antagonists 95
DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. 95
Antimyocardial autoimmunity in ischemic coronary disease 95
FAS -670 gene promoter polymorphism confers susceptibility to systemic sclerosis 95
AIDS e neoplasie 95
SAT0489 Biologic Therapies and Infections in The Daily Practice: A Study on Historical Cohort from 3 Italian Rheumatologic Units 95
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. 95
The role of cytokines in the pathogenesis of PSS: an overview 95
Gamma-delta T cells are not involved in the natural and antibody-dependent cytotoxicity of peripheral blood mononuclear cells in inflammatory bowel disease. 95
Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. 94
Natural killer cell frequency and function in patients with monoclonal gammopathies. 94
Totale 11.276
Salva come PNG Salva come JPEG
Categoria #
all - tutte 176.222
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 176.222
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.215 0 0 0 0 0 142 505 24 470 129 758 187
2021/20222.529 134 240 441 174 103 26 21 152 189 131 179 739
2022/20237.628 605 368 158 745 734 854 15 537 3.241 57 213 101
2023/20241.937 418 114 116 257 149 476 33 103 10 81 52 128
2024/20257.471 135 151 757 232 840 631 975 632 1.824 304 480 510
2025/20266.171 692 1.366 712 1.557 1.195 649 0 0 0 0 0 0
Totale 38.260